Perrigo Steps Up European Consumer Health Focus In Omega Pharma Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Perrigo will acquire Belgian firm Omega Pharma, which distributes more than 2,000 products to 211,000 pharmacists, 105,000 retailers and 3,900 pharmacies. The firm also resumes shipments of generic guaifenesin 600 mg in the U.S. after ingredient supply problems derailed marketing for more than two years.
You may also be interested in...
Omega Pharma Acquires Six Glaxo OTC Brands, But Alli Lingers
Omega Pharma will pay $619 million for GSK’s Lactacyd feminine wash products, Abtei supplements, Solpadeine analgesics, Zantac antacid, Nytol sleep aids and the allergy drug Beconase. The deal is part of Glaxo’s plan to simplify its consumer business by selling 19 OTC brands.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.